Why Are NanoViricides Shares Gaining Today
Portfolio Pulse from Vandana Singh
NanoViricides Inc (NNVC) shares are trading higher after the company reported positive preclinical data for its antiviral clinical drug candidate NV-387 for Respiratory Syncytial Virus (RSV). NV-387 is also the active ingredient of NV-CoV-2, the company's drug for COVID. The company plans to advance NV-387 into Phase 2 studies against RSV once the current Phase 1 studies of NV-CoV-2 are completed. GSK plc's (GSK) Arexvy and Pfizer Inc's (PFE) Abrysvo have recently been approved for RSV prophylaxis.
July 11, 2023 | 4:51 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
GSK plc's Arexvy has recently been approved for RSV prophylaxis.
The approval of GSK plc's Arexvy for RSV prophylaxis is a positive development for the company. However, as it is mentioned in the context of NanoViricides Inc's development, the relevance is not as high.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
NanoViricides Inc's shares are trading higher due to positive preclinical data for its antiviral drug candidate NV-387.
The positive preclinical data for NV-387, which is also the active ingredient in the company's COVID drug, has led to an increase in the company's share price. The company's plan to advance NV-387 into Phase 2 studies against RSV also contributes to the positive impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Pfizer Inc's Abrysvo has recently been approved for RSV prophylaxis.
The approval of Pfizer Inc's Abrysvo for RSV prophylaxis is a positive development for the company. However, as it is mentioned in the context of NanoViricides Inc's development, the relevance is not as high.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50